Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib + Ruxolitinib in Myelofibrosis
NCT04551066Phase 3Terminated
- Sponsor
- Incyte
- Start
- May 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Group A: Parsaclisib + Ruxolitinib with Group B: Placebo + Ruxolitinib (2 arms). Primary endpoint: Spleen Volume Reduction ≥35% at 24 weeks. Started May 2021; status: terminated.
02
Drugs
parsaclisib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04551066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551066.